HCYTMAG-60K-PX29
MILLIPLEX® Human Cytokine/Chemokine Magnetic Bead Panel - Premixed 29 Plex - Immunology Multiplex Assay
Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.
Synonym(s):
Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12161503
eCl@ss:
32161000
Recommended Products
species reactivity
human
manufacturer/tradename
Milliplex®
assay range
accuracy: 87-107%
standard curve range: 3.2-10,000 pg/mL
technique(s)
multiplexing: suitable
compatibility
configured for Premixed
detection method
fluorometric (Luminex xMAP)
shipped in
wet ice
General description
“Cytokine” is a general term used for a diverse group of soluble proteins and peptides which act as regulators under both normal and pathological conditions to modulate the functional activities of individual cells and tissues. These proteins also mediate direct interactions between cells and regulate processes taking place in the extracellular environment. Cytokines differ from hormones in that they act on a wider spectrum of target cells. Also, unlike hormones, they are not produced by specialized cells which are organized in specialized glands. The cytokine group of proteins includes lymphokines, interferons, colony stimulating factors and chemokines. Cytokine and chemokine research plays a significant role in achieving a deeper understanding of the immune system and its multi-faceted response to most antigens, as well as disease states such as inflammatory disease, allergic reactions, irritable bowel disease (IBD), sepsis, and cancer.
The MILLIPLEX® Human Cytokine / Chemokine Panel 1 enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cytokines/Chemokines
The MILLIPLEX® Human Cytokine / Chemokine Panel 1 enables you to focus on the therapeutic potential of cytokines as well as the modulation of cytokine expression.
The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.
Panel Type: Cytokines/Chemokines
Specificity
Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.
Application
- Analytes: EGF, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, TNF-β, VEGF, Eotaxin/CCL11
- Recommended Sample type: Serum, plasma, or tissue/cell lysate and culture supernatant samples
- Recommended Sample dilution: Neat plasma or serum. Tissue culture supernatant may require a dilution with an appropriate control medium prior to assay.
- Assay Run Time: Overnight or two-hour primary incubation. For best results, an overnight incubation is recommended
- Research Category: Inflammation & Immunology
- Research Subcategory: Obesity, Metabolic Disorders, Inflammation & Autoimmune Mechanisms
Packaging
96 well plate
Storage and Stability
Recommended storage for kit components is 2 - 8°C.
Other Notes
Note: RANTES, PDGF-AA and PDGF-AB/AA cannot be plexed with other analytes for serum/plasma.
Sensitivity: Refer to kit protocol for sensitivities for individual cytokines/chemokines.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Rachel Lam et al.
International journal of environmental research and public health, 17(12) (2020-06-21)
World Trade Center particulate matter (WTC-PM)-exposed firefighters with metabolic syndrome (MetSyn) have a higher risk of WTC lung injury (WTC-LI). Since macrophages are crucial innate pulmonary mediators, we investigated WTC-PM/lysophosphatidic acid (LPA) co-exposure in macrophages. LPA, a low-density lipoprotein metabolite
Rodolfo Soria-Castro et al.
Journal of leukocyte biology (2021-06-01)
The immune response plays a critical role in the pathophysiology of SARS-CoV-2 infection ranging from protection to tissue damage and all occur in the development of acute respiratory distress syndrome (ARDS). ARDS patients display elevated levels of inflammatory cytokines and
Ellen Kraig et al.
Experimental gerontology, 105, 53-69 (2018-02-07)
Inhibition of the mechanistic target of rapamycin (mTOR) pathway by rapamycin (RAPA), an FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ allograft rejection, enhances longevity in mice. Importantly, RAPA was efficacious even when initiated in relatively
Shulian Wang et al.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 126(3), 506-510 (2018-03-03)
To study whether cytokine markers may improve predictive accuracy of radiation esophagitis (RE) in non-small cell lung cancer (NSCLC) patients. A total of 129 patients with stage I-III NSCLC treated with radiotherapy (RT) from prospective studies were included. Thirty inflammatory
B Dominguez-Molina et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 64(5), 621-628 (2016-12-18)
HIV-1-controllers maintain HIV-1 viremia at low levels (normally <2000 HIV-RNA copies/mL) without antiretroviral treatment. However, some HIV-1-controllers have evidence of immunologic progression with marked CD4+T-cell decline. We investigated host genetic factors associated with protection against CD4+T-cell loss in HIV-1-controllers. We
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service